<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Effect of diuretics on magnesium handling by the kidney</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Effect of diuretics on magnesium handling by the kidney</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Effect of diuretics on magnesium handling by the kidney</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan S L Yu, MB, BChir</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sri G Yarlagadda, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Approximately 2.5 g of magnesium (100 mmol) is filtered by the glomerulus every day. Under normal conditions, 95 percent of the filtered magnesium is reabsorbed, and 5 percent is excreted. Reabsorption of magnesium occurs via both paracellular and transcellular processes. (See  <a class="medical medical_review" href="/z/d/html/844.html" rel="external">"Regulation of magnesium balance"</a>.)</p><p>Diuretics are widely used in the treatment of hypertension, heart failure, cirrhosis, and kidney diseases. Three types of diuretics are known to influence magnesium homeostasis:</p><p class="bulletIndent1"><span class="glyph">●</span>Loop diuretics</p><p class="bulletIndent1"><span class="glyph">●</span>Thiazide-type diuretics</p><p class="bulletIndent1"><span class="glyph">●</span>Potassium-sparing diuretics</p><p></p><p>Loop and thiazide diuretics can enhance urinary magnesium losses, although by different mechanisms [<a href="#rid1">1,2</a>], while potassium-sparing diuretics can reduce magnesium excretion. Before the glomerular filtrate reaches the loop of Henle, approximately 15 to 25 percent of the filtered magnesium load is reabsorbed by the proximal tubule. Although the mechanism is not well understood, magnesium reabsorption by the proximal tubule appears to involve a paracellular process that depends upon sodium and water transport. A small lumen-positive potential in the early proximal tubule also adds to the driving force [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/844.html" rel="external">"Regulation of magnesium balance"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">LOOP DIURETICS</span><span class="headingEndMark"> — </span>Filtered sodium chloride enters the cells in the thick ascending limb of the loop of Henle via Na-K-2Cl cotransporters in the apical (luminal) membrane (<a class="graphic graphic_figure graphicRef75301" href="/z/d/graphic/75301.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>]. Although this process is electrically neutral, some of the reabsorbed potassium leaks back into the lumen to drive further sodium chloride transport. This movement of cationic potassium makes the lumen relatively electropositive, thereby creating an electrical gradient that promotes the passive paracellular (between cells) reabsorption of sodium and divalent cations, such as magnesium and calcium. (See  <a class="medical medical_review" href="/z/d/html/2340.html" rel="external">"Diuretics and calcium balance"</a>.)</p><p>Paracellular magnesium reabsorption appears to be facilitated by the tight junction proteins, claudin-16 and -19. Mutations in the genes encoding these proteins cause familial hypomagnesemic hypercalciuria with nephrocalcinosis [<a href="#rid5">5,6</a>]. (See  <a class="medical medical_review" href="/z/d/html/829.html" rel="external">"Hypomagnesemia: Causes of hypomagnesemia", section on 'Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)'</a>.)</p><p>Loop diuretics act by competing for the chloride site on the Na-K-2Cl cotransporter [<a href="#rid4">4</a>]. Inhibiting sodium chloride reabsorption also inhibits the back leak of potassium and the generation of the lumen-positive potential, thereby decreasing the electrical gradient for magnesium reabsorption and increasing urinary magnesium excretion. Net magnesium transport is inhibited to a greater degree than sodium at any given luminal <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> concentration because magnesium (as a divalent cation) is influenced by the voltage change to a greater degree than sodium and potassium (which are monovalent cations) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/2338.html" rel="external">"Mechanism of action of diuretics"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">THIAZIDE DIURETICS</span><span class="headingEndMark"> — </span>Magnesium reabsorption in the distal nephron is thought to occur primarily in the distal convoluted tubule via a transcellular (across cells) mechanism. Entry of filtered magnesium into the cell in this segment is mediated by a channel in the luminal membrane called TRPM6 (transient receptor potential cation channel melastatin) [<a href="#rid8">8</a>]; magnesium entry into the cell is enhanced by the favorable electrochemical gradient across the luminal membrane [<a href="#rid9">9</a>]. There is some evidence that the exit mechanism in the basolateral membrane (which returns the reabsorbed magnesium to the peritubular capillary) could involve a sodium-magnesium exchange [<a href="#rid10">10</a>]. The driving force for this exchange is the low sodium concentration inside the cell (10 to 15 mEq/L) compared with that in the extracellular fluid, thereby favoring sodium entry and subsequent magnesium exit.</p><p>The thiazide-type diuretics decrease sodium chloride reabsorption in the distal tubule by inhibiting electroneutral Na-Cl cotransporters in the apical membrane that are responsible for the entry of luminal sodium and chloride into the cell (<a class="graphic graphic_figure graphicRef64975" href="/z/d/graphic/64975.html" rel="external">figure 2</a>) [<a href="#rid4">4</a>]. The effect of thiazide diuretics on magnesium transport may vary with acute or chronic administration. In isolated distal tubular cells, the acute inhibition of entry of sodium chloride leads to increased uptake of magnesium [<a href="#rid11">11</a>]. Chronic administration as is normally encountered clinically, however, tends to increase magnesium excretion [<a href="#rid1">1,2</a>]. This seemingly paradoxical effect may be due to several mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic administration of thiazides or the genetic absence of the Na-Cl cotransporters reduces kidney expression levels of TRPM6 in mice [<a href="#rid12">12</a>]. This mechanism explains the magnesium wasting seen in Gitelman syndrome, in which a mutation in the distal tubule Na-Cl cotransporter produces a situation equivalent to continuous thiazide diuretic administration. (See  <a class="medical medical_review" href="/z/d/html/2344.html" rel="external">"Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic administration of thiazides is frequently associated with negative potassium balance and hypokalemia. Hypokalemia may in turn directly inhibit distal tubular cell magnesium uptake, thereby increasing magnesium excretion [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H431818357"><span class="h1">POTASSIUM-SPARING DIURETICS</span><span class="headingEndMark"> — </span>Sodium reabsorption by collecting tubule cells is electrogenic because positively charged sodium is reabsorbed without an anion (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 3</a>), making the lumen electronegative. This creates an unfavorable electrical gradient that inhibits magnesium reabsorption. Potassium-sparing diuretics (<a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">amiloride</a>, <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">triamterene</a>, and <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>) decrease sodium entry mediated by epithelial sodium channels in the connecting tubule and cortical collecting tubule [<a href="#rid4">4</a>], an effect that enhances magnesium reabsorption. Thus, these agents decrease magnesium excretion [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H2753535994"><span class="h1">OSMOTIC DIURETICS</span><span class="headingEndMark"> — </span>Sodium-glucose cotransporter 2 (SGLT2) inhibitors (<a class="drug drug_general" data-topicid="88901" href="/z/d/drug information/88901.html" rel="external">canagliflozin</a>, <a class="drug drug_general" data-topicid="93383" href="/z/d/drug information/93383.html" rel="external">dapagliflozin</a>, <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a>, and ipragliflozin) are being increasingly used to treat diabetes, heart failure, and chronic kidney disease. Although they are not formally considered as diuretic agents, their ability to increase luminal glucose concentrations in the proximal tubule can induce an osmotic diuresis. (See  <a class="medical medical_review" href="/z/d/html/109245.html" rel="external">"Sodium-glucose cotransporter 2 inhibitors for the treatment of hyperglycemia in type 2 diabetes mellitus", section on 'Mechanism of action'</a>.)</p><p>Since approximately 10 to 25 percent of the filtered load of magnesium is reabsorbed in the proximal tubule, it might be expected that SGLT2 inhibitors would lead to urinary loss of magnesium. In practice, however, SGLT2 inhibitors have been observed to induce mild increases, ranging from 0.1 to 0.24 mg/dL in serum magnesium levels in patients with type 2 diabetes, and this appears to be a class effect [<a href="#rid15">15,16</a>]. The mechanisms for this effect are not well understood. One possibility is that decreased glomerular filtration rate (GFR) induced by SGLT2 inhibitors decreases the filtered load of magnesium. In addition, decreased electrogenic sodium-coupled glucose transport in the proximal tubule is expected to make the luminal voltage more positive, increasing the driving force for passive paracellular magnesium reabsorption. Alternatively, it has been proposed that altered glucose metabolism may be responsible. As an example, SGLT2 inhibitors could increase glucagon, which promotes tubular magnesium reabsorption. Finally, there may be extrarenal effects, such as upregulating intestinal magnesium absorption in some way.</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL EFFECTS OF DIURETICS ON MAGNESIUM</span><span class="headingEndMark"> — </span>Mild magnesium depletion appears to be relatively common after loop or thiazide diuretic therapy [<a href="#rid1">1</a>], and these drugs occasionally produce hypomagnesemia. (See  <a class="medical medical_review" href="/z/d/html/829.html" rel="external">"Hypomagnesemia: Causes of hypomagnesemia", section on 'Renal losses'</a>.)</p><p>However, in patients treated with magnesium-wasting diuretics, the serum magnesium concentration often remains within or near the normal range, possibly because most of the losses come from the cells [<a href="#rid14">14,17</a>]. However, preferential intracellular loss has not been a uniform finding [<a href="#rid1">1</a>].</p><p>The incidence and clinical importance of magnesium depletion without hypomagnesemia are uncertain. It has been proposed (although clearly not proven [<a href="#rid18">18</a>]) that these patients may be at increased risk for cardiac arrhythmias, particularly if they are also hypokalemic. (See  <a class="medical medical_review" href="/z/d/html/846.html" rel="external">"Significance of hypomagnesemia in cardiovascular disease"</a>.)</p><p>Conversely, sodium-glucose cotransporter 2 (SGLT2) inhibitors have been reported to be quite effective in correcting refractory hypomagnesemia, with increases in serum magnesium ranging from 0.3 to 1 mg/dL [<a href="#rid19">19,20</a>]. Remarkably, this beneficial effect has been observed in both patients with and without diabetes, in both renal and nonrenal hypomagnesemia, and is not consistently associated with reduction in magnesuria.</p><p class="headingAnchor" id="H160742216"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles </strong>– Approximately 2.5 g of magnesium (100 mmol) is filtered by the glomerulus every day. Under normal conditions, 95 percent of the filtered magnesium is reabsorbed, and 5 percent is excreted. Diuretics are widely used in the treatment of hypertension, heart failure, cirrhosis, and kidney diseases. Loop and thiazide diuretics can enhance urinary magnesium losses, although by different mechanisms, while potassium-sparing diuretics can reduce magnesium excretion. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loop diuretics </strong>– Filtered sodium chloride enters the cells in the thick ascending limb of the loop of Henle via Na-K-2Cl cotransporters in the apical (luminal) membrane (<a class="graphic graphic_figure graphicRef75301" href="/z/d/graphic/75301.html" rel="external">figure 1</a>). Some reabsorbed potassium leaks back into the lumen, making the lumen relatively electropositive and thereby creating an electrical gradient that promotes the passive paracellular (between cells) reabsorption of magnesium. Loop diuretics act by competing for the chloride site on the Na-K-2Cl cotransporter. Inhibiting sodium chloride reabsorption also inhibits the back leak of potassium and the generation of the lumen-positive potential, thereby decreasing the electrical gradient for magnesium reabsorption and increasing urinary magnesium excretion. (See <a class="local">'Loop diuretics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiazide diuretics </strong>– Magnesium reabsorption in the distal nephron is thought to occur primarily in the distal convoluted tubule via a transcellular (across cells) mechanism. Entry of filtered magnesium into the cell in this segment is mediated by a channel in the luminal membrane called TRPM6 (transient receptor potential cation channel melastatin). Chronic administration of thiazide diuretics tends to increase magnesium excretion, possibly by reducing kidney expression levels of TRPM6 and inducing hypokalemia, which may in turn directly inhibit distal tubular cell magnesium uptake. (See <a class="local">'Thiazide diuretics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potassium-sparing diuretics </strong>– Sodium reabsorption by collecting tubule cells is electrogenic because positively charged sodium is reabsorbed without an anion (<a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">figure 3</a>), making the lumen electronegative. This creates an unfavorable electrical gradient that inhibits magnesium reabsorption. Potassium-sparing diuretics decrease sodium entry mediated by epithelial sodium channels in the connecting tubule and cortical collecting tubule, an effect that enhances magnesium reabsorption. (See <a class="local">'Potassium-sparing diuretics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osmotic diuretics </strong>– Sodium-glucose cotransporter 2 (SGLT2) inhibitors are not formally considered as diuretic agents, but their ability to increase luminal glucose concentrations in the proximal tubule can induce an osmotic diuresis. While SGLT2 inhibitors might be expected to lead to urinary loss of magnesium, SGLT2 inhibitors have been observed in practice to induce mild increases in serum magnesium levels in patients with type 2 diabetes, and this appears to be a class effect. The mechanisms for this effect are not well understood. (See <a class="local">'Osmotic diuretics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical effects of diuretics on magnesium </strong>– Mild magnesium depletion appears to be relatively common after loop or thiazide diuretic therapy, and these drugs occasionally produce hypomagnesemia. However, in patients treated with diuretics, the serum magnesium concentration often remains within or near the normal range, possibly because most of the losses come from the cells. (See <a class="local">'Clinical effects of diuretics on magnesium'</a> above.)</p><p></p><p class="headingAnchor" id="H1065483"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Zalman S Agus, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA 1992; 267:1083.</a></li><li><a class="nounderline abstract_t">Ryan MP. Diuretics and potassium/magnesium depletion. Directions for treatment. Am J Med 1987; 82:38.</a></li><li><a class="nounderline abstract_t">Quamme GA, Smith CM. Magnesium transport in the proximal straight tubule of the rabbit. Am J Physiol 1984; 246:F544.</a></li><li><a class="nounderline abstract_t">Ellison DH. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis 1994; 23:623.</a></li><li><a class="nounderline abstract_t">Simon DB, Lu Y, Choate KA, et al. Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 1999; 285:103.</a></li><li><a class="nounderline abstract_t">Kausalya PJ, Amasheh S, Günzel D, et al. Disease-associated mutations affect intracellular traffic and paracellular Mg2+ transport function of Claudin-16. J Clin Invest 2006; 116:878.</a></li><li><a class="nounderline abstract_t">Quamme GA. Effect of furosemide on calcium and magnesium transport in the rat nephron. Am J Physiol 1981; 241:F340.</a></li><li><a class="nounderline abstract_t">Voets T, Nilius B, Hoefs S, et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 2004; 279:19.</a></li><li><a class="nounderline abstract_t">Quamme GA. Renal magnesium handling: new insights in understanding old problems. Kidney Int 1997; 52:1180.</a></li><li><a class="nounderline abstract_t">Xi Q, Hoenderop JG, Bindels RJ. Regulation of magnesium reabsorption in DCT. Pflugers Arch 2009; 458:89.</a></li><li><a class="nounderline abstract_t">Dai LJ, Friedman PA, Quamme GA. Cellular mechanisms of chlorothiazide and cellular potassium depletion on Mg2+ uptake in mouse distal convoluted tubule cells. Kidney Int 1997; 51:1008.</a></li><li><a class="nounderline abstract_t">Nijenhuis T, Vallon V, van der Kemp AW, et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005; 115:1651.</a></li><li><a class="nounderline abstract_t">Dai LJ, Raymond L, Friedman PA, Quamme GA. Mechanisms of amiloride stimulation of Mg2+ uptake in immortalized mouse distal convoluted tubule cells. Am J Physiol 1997; 272:F249.</a></li><li><a class="nounderline abstract_t">Dyckner T, Wester PO, Widman L. Amiloride prevents thiazide-induced intracellular potassium and magnesium losses. Acta Med Scand 1988; 224:25.</a></li><li><a class="nounderline abstract_t">Tang H, Zhang X, Zhang J, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 2016; 59:2546.</a></li><li><a class="nounderline abstract_t">Toto RD, Goldenberg R, Chertow GM, et al. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. J Diabetes Complications 2019; 33:107402.</a></li><li><a class="nounderline abstract_t">Dørup I, Skajaa K, Clausen T, Kjeldsen K. Reduced concentrations of potassium, magnesium, and sodium-potassium pumps in human skeletal muscle during treatment with diuretics. Br Med J (Clin Res Ed) 1988; 296:455.</a></li><li><a class="nounderline abstract_t">Dai LJ, Quamme GA. Intracellular Mg2+ and magnesium depletion in isolated renal thick ascending limb cells. J Clin Invest 1991; 88:1255.</a></li><li><a class="nounderline abstract_t">Shah CV, Robbins TS, Sparks MA. Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases. Kidney Med 2022; 4:100533.</a></li><li><a class="nounderline abstract_t">Ray EC, Boyd-Shiwarski CR, Liu P, et al. SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients. Kidney Med 2020; 2:359.</a></li></ol></div><div id="topicVersionRevision">Topic 2335 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1735925" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3551599" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diuretics and potassium/magnesium depletion. Directions for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6720959" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Magnesium transport in the proximal straight tubule of the rabbit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172204" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diuretic drugs and the treatment of edema: from clinic to bench and back again.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10390358" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16528408" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Disease-associated mutations affect intracellular traffic and paracellular Mg2+ transport function of Claudin-16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7315959" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of furosemide on calcium and magnesium transport in the rat nephron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576148" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9350641" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Renal magnesium handling: new insights in understanding old problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18949482" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Regulation of magnesium reabsorption in DCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9083264" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cellular mechanisms of chlorothiazide and cellular potassium depletion on Mg2+ uptake in mouse distal convoluted tubule cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902302" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9124403" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mechanisms of amiloride stimulation of Mg2+ uptake in immortalized mouse distal convoluted tubule cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3414406" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Amiloride prevents thiazide-induced intracellular potassium and magnesium losses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27628105" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31375422" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2450616" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Reduced concentrations of potassium, magnesium, and sodium-potassium pumps in human skeletal muscle during treatment with diuretics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1655827" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intracellular Mg2+ and magnesium depletion in isolated renal thick ascending limb cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36185705" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32734255" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
